Sen. Grassley’s Comment on the Medicare Trustees’ Annual Report
Senator Chuck Grassley, Ranking Member of the Committee on Finance, issued the comment below about the report issued today by the trustees of Social Security and Medicare. “This year’s Medicare Trustees’ report is further proof that the rapid growth in entitlement spending is a serious problem. Earlier this year, heads of the Federal Reserve, the […]
Grassley: Democratic Leaders Miss Boat on Tax Relief, Abuse Crackdowns
Sen. Chuck Grassley, ranking member of the Committee on Finance, tonight made the following comment on the House-Senate Democrats’ agreement on a tax package to include in the supplemental spending bill. “The point of this package was to give tax relief to small businesses to counteract the effects of the minimum wage increase and otherwise […]
Tax Gap News: GAO Reports to Baucus, Grassley
Washington, DC – A Government Accountability Office (GAO) review of an Internal Revenue Service (IRS) research project has outlined 14 opportunities for IRS to identify and collect more unpaid taxes. At the request of Finance Committee Chairman Max Baucus (D-Mont.) and Ranking Republican Chuck Grassley (R-Iowa), GAO looked at the National Research Project that IRS […]
Grassley Warns of Lingering AMT Threat for Taxpayers
Mr. President, yesterday was tax return filing day for most Americans for the 2006 tax year. While filing that 2006 tax return and paying tax owed for 2006 was stressful enough, for the 23 million families that will be AMT taxpayers in 2007 there was added stress. That added stress is due to the fact […]
Sen. Grassley’s Pre-Cloture Vote Statement on S.3, to Allow a Government Takeover of Negotiations of Medicare Part D Prescription Drug Prices
Mr. President, I have always been fond of jigsaw puzzles. Spinning the pieces around– figuring out how they all fit together … until you finally you see the whole picture. This debate is a lot like working a jigsaw puzzle. Let’s take a look at a few of the pieces. You have H.R.4, the bill […]
Sen. Grassley’s Post-Cloture Vote Statement on S.3, to Allow a Government Takeover of Negotiations of Medicare Part D Prescription Drug Prices
Mr. President, I want to make a couple of points in response to comments made about this morning’s vote on S. 3. Members on the other side of the aisle, including the Assistant Majority Leader, said that Republicans don’t want this debate. Don’t want the debate? This body has debated the so-called prohibition on government […]
Floor Statement of Senator Grassley on the FDA Revitalization Act of 2007
Mr. President, today I want to speak about a topic that I have spoken about many times before: drug safety. However today is a little different. Earlier today the Committee on Health, Education, Labor, and Pensions began marking up S. 1082, the Food and Drug Administration Revitalization Act. For the first time in almost a […]
Grassley: IRS Commissioner Will Bring Skills to Red Cross Position
Sen. Chuck Grassley, ranking member and immediate past chairman of the Committee on Finance, with jurisdiction over taxes, has worked to reform governance practices of tax-exempt organizations such as the American Red Cross. Last month, the Senate passed Grassley’s legislation to reform the Red Cross, developed with the organization’s leadership and initiative. This week, the […]
Grassley: Taxpayers Face Wall of Tax Increases if Democratic Leaders Don’t Act
We just went through that time of year where, for most people, the tax code transforms from an abstraction to a concrete reality. The same is true of tax relief. What may be an academic or policy discussion becomes something more when the men and women of our nation actually work out how much of […]
Sen. Grassley Says New Consumer Reports Poll Further Demonstrates Need for Bold Reform of FDA
Sen. Chuck Grassley issued the comment below about the poll released today by Consumer Reports about how Americans view the government’s performance in ensuring the safety of prescription drugs. In January, Sen. Grassley and Sen. Christopher Dodd reintroduced two bills to revamp and prioritize the post-market surveillance process within the Food and Drug Administration and […]